Thursday, June 26, 2014
Publication and contact
Epidermal growth factor receptor (EGFR);
necrosis factor receptor superfamily member 9 (TNFRSF9;
Studies in mice and human
samples suggest sequential treatment with anti-EGFR and anti-CD137 antibodies
could help treat EGFR+ tumors. In EGFR+ mouse
xenograft and syngeneic tumor models, the anti-EGFR mAb Erbitux
increased the number of Cd137+ NK cells in
blood, spleen and tumors, and subsequent treatment with BMS-663513,
an anti-CD137 antibody, increased tumor regression and prolonged survival
compared with either antibody alone. In samples from patients with head and
neck cancer, Erbitux increased the number of CD137+ NK cells by 4%-15% compared with pretreatment
numbers. Next steps include designing a clinical trial of anti-EGFR plus
Lilly and Co., Bristol-Myers
Squibb Co. and Merck
KGaA market Erbitux to treat colorectal and head and neck
Inc. markets the anti-EGFR mAb Vectibix
to treat colorectal and other types of cancer.
BMS-663513 is in Phase I trials to treat solid tumors.
Inc.'s anti-CD137 antibody, PF-05082566,
is in Phase I trials to treat cancers including non-Hodgkin's lymphoma (NHL).
Published online June 26, 2014
Patent and licensing status
Kohrt, H.E. et al. J.
Clin. Invest.; published online May 16, 2014;
Contact: Holbrook E. Kohrt, Stanford University Medical
Center, Stanford, Calif.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]